NVP-DKY709

CAS No. 2291360-73-9

NVP-DKY709 ( —— )

Catalog No. M28913 CAS No. 2291360-73-9

NVP-DKY709 is a potent IKZF2 inhibitor for the treatment of cancers.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 219 Get Quote
10MG 350 Get Quote
25MG 587 Get Quote
50MG 835 Get Quote
100MG 1134 Get Quote
500MG 2277 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    NVP-DKY709
  • Note
    Research use only, not for human use.
  • Brief Description
    NVP-DKY709 is a potent IKZF2 inhibitor for the treatment of cancers.
  • Description
    NVP-DKY709 is a potent IKZF2 inhibitor for the treatment of cancers.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Apelin receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2291360-73-9
  • Formula Weight
    417.5
  • Molecular Formula
    C25H27N3O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Trifonov L, et al. An Expedient Synthesis of CMF-019: (S)-5-Methyl-3-{1-(pentan-3-yl)-2- (thiophen-2-ylmethyl)-1H-benzo[d]imidazole-5-carboxamido}hexanoic Acid, a Potent Apelin Receptor (APJ) Agonist. Med Chem. 2018;14(7):688-694.
molnova catalog
related products
  • Glycodeoxycholic aci...

    Glycodeoxycholic Acid induces apoptosis in hepatocytes by a mechanism associated with DNA cleavage by endonucleases. It is a secondary bile acid produced by the action of enzymes existing in the microbial flora of the colonic environment.

  • KN-92 phosphate

    KN-92 is an inactive derivative of KN-93. KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII).

  • Elamipretide 2TFA

    Elamipretide is a novel mitochondrion-targeted antioxidant.?Treatment with elamipretide significantly ameliorated LPS-induced learning and memory impairment during behavioral tests.